SYRE vs. SWTX, RNA, RARE, ACLX, PTGX, AAPG, SRRK, MTSR, KYMR, and VKTX
Should you be buying Spyre Therapeutics stock or one of its competitors? The main competitors of Spyre Therapeutics include SpringWorks Therapeutics (SWTX), Avidity Biosciences (RNA), Ultragenyx Pharmaceutical (RARE), Arcellx (ACLX), Protagonist Therapeutics (PTGX), Ascentage Pharma Group International (AAPG), Scholar Rock (SRRK), Metsera (MTSR), Kymera Therapeutics (KYMR), and Viking Therapeutics (VKTX). These companies are all part of the "pharmaceutical products" industry.
Spyre Therapeutics vs. Its Competitors
SpringWorks Therapeutics (NASDAQ:SWTX) and Spyre Therapeutics (NASDAQ:SYRE) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.
Spyre Therapeutics has lower revenue, but higher earnings than SpringWorks Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks.
80.4% of Spyre Therapeutics shares are held by institutional investors. 7.8% of SpringWorks Therapeutics shares are held by company insiders. Comparatively, 15.4% of Spyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
SpringWorks Therapeutics currently has a consensus price target of $52.57, suggesting a potential upside of 11.88%. Spyre Therapeutics has a consensus price target of $53.40, suggesting a potential upside of 237.12%. Given Spyre Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Spyre Therapeutics is more favorable than SpringWorks Therapeutics.
In the previous week, SpringWorks Therapeutics had 3 more articles in the media than Spyre Therapeutics. MarketBeat recorded 4 mentions for SpringWorks Therapeutics and 1 mentions for Spyre Therapeutics. SpringWorks Therapeutics' average media sentiment score of 0.54 beat Spyre Therapeutics' score of 0.00 indicating that SpringWorks Therapeutics is being referred to more favorably in the media.
Spyre Therapeutics has a net margin of 0.00% compared to SpringWorks Therapeutics' net margin of -115.60%. SpringWorks Therapeutics' return on equity of -51.10% beat Spyre Therapeutics' return on equity.
SpringWorks Therapeutics has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 2.68, meaning that its share price is 168% more volatile than the S&P 500.
Summary
Spyre Therapeutics beats SpringWorks Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Spyre Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spyre Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SYRE) was last updated on 7/4/2025 by MarketBeat.com Staff
Free SYRE Stock Alerts